|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Johnson & Johnson (JNJ) to Pay $1 Billion to Settle Risperdal Marketing Probe
1/6/2012 8:07:41 AM
Johnson & Johnson will pay more than $1 billion in civil and criminal penalties to the federal government and individual states to settle an investigation into the marketing practices of its anti-psychotic drug Risperdal, Bloomberg News Service reported Thursday. The figure would be in line with what Eli Lilly & Co. paid three years ago to settle claims that it marketed a similar anti-psychotic drug, Zyprexa, for illnesses that weren’t approved by the U.S. Food and Drug Administration. “These pharmaceutical companies are going to be running, not walking, to the settlement table,” Patrick Burns, spokesman for Taxpayers Against Fraud, a Washington, D.C., consumer group, told New Jersey Press Media. “The numbers are going up very rapidly.”
|
|
|
|
|
|
|
|
|
|
|